YOU WONT BELIEVE: Enanta pharmaceuticals - You Need To See This

Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpatient adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the elderly and/or those with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) or…

Benzinga · Sep 29, 2025

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga · Jul 29, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022

Upgrades

Benzinga · Jul 6, 2022

Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial Virus (RSV).

Benzinga · May 18, 2022

What 4 Analyst Ratings Have To Say About Enanta Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Enanta Pharmaceuticals (NASDAQ:ENTA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · May 12, 2022

Where Enanta Pharmaceuticals Stands With Analysts

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:

Benzinga · Feb 9, 2022

Enanta Pharmaceuticals: Q1 Earnings Insights

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q1 earnings results on Tuesday, February 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Benzinga · Feb 8, 2022